IMESCIA is a deeptech start-up in the field of oncology. We are a spin-off from the Institut Galien Paris-Sud (IGPS), a joint research unit of the CNRS and the Faculty of Pharmacy of Paris-Sud University (Châtenay-Malabry). We are developing a technology for subcutaneous (SC) delivery of anticancer drugs currently administered only intravenously (IV). Our technology relies on a novel prodrug polymer approach that effectively inhibits local toxicities and enhances the treatment’s efficacy. You will be joining a team of young and motivated entrepreneurs and scientists to develop our cutting-edge technology.

The full description of the job offer is available here.

Contact and details:

Alexandre Bordat co-founder and CTO:

Imescia is in Châtenay-Malabry, near Paris.